

NOTICE: This is a translation of a notice in Japanese issued on June 24, 2015 and is made solely for the convenience of foreign shareholders. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

Securities code: 4536

June 24, 2015

**RESOLUTION NOTICE OF
THE 103RD ANNUAL GENERAL MEETING OF SHAREHOLDERS OF
SANTEN PHARMACEUTICAL CO., LTD.**

Dear Shareholder:

We hereby inform you of the reports and the resolutions that were made, as set forth below, in the 103rd Annual General Meeting of Shareholders of the Company that was held today.

Reports:

1. Reports on the Business Report, Consolidated Financial Statements and Financial Statements for the 103rd Business Term (April 1, 2014 to March 31, 2015)
2. Reports on the Audit Reports by the Accounting Auditors and the Board of Corporate Auditors on the Consolidated Financial Statements for the 103rd Business Term (April 1, 2014 to March 31, 2015)

As regards the items set forth above, the contents thereof were reported.

Resolved Items:

Proposal No. 1: Appropriation of Surplus

As regards this item, the term-end dividends of profits were resolved to be JPY 60 per share as per the original proposal. Consequently, the total dividends for the annual business term, including the interim dividends previously distributed are JPY 110 per share, which means a dividend increase of JPY 10 per share compared to the previous business term.

Proposal No. 2: Appointment of Five (5) Directors

As regards this item, Akira Kurokawa, Sadatoshi Furukado, Akihiro Okumura, Takayuki Katayama and Kanoko Oishi were appointed as per the original proposal; each of them assumed their respective offices.

Akihiro Okumura, Takayuki Katayama and Kanoko Oishi are Outside Directors.

Proposal No. 3: Appointment of Two (2) Corporate Auditors

As regards this item, Yutaka Mizuno and Seiichiro Adachi were appointed as per the original proposal; each of them assumed their respective offices.

Yutaka Mizuno and Seiichiro Adachi are Outside Corporate Auditors.

Yours very truly,

Akira Kurokawa
Representative Director
President & CEO
SANTEN PHARMACEUTICAL CO., LTD.
9-19, Shimoshinjo 3-chome, Higashiyodogawa-ku, Osaka, Japan
[Corporate Headquarters: 4-20, Ofuka-cho, Kita-ku, Osaka, Japan]

ANNOUNCEMENT

At the Board of Directors meeting, which was held after the close of this Annual General Meeting of Shareholders, Akira Kurokawa was appointed as President and CEO. He assumed the said offices.

As a result thereof, the Directors and Corporate Auditors of the Company and Corporate Officers of the Company on and after July 1, 2015 shall be as follows:

Directors and Corporate Auditors

Akira Kurokawa	President and CEO
Sadatoshi Furukado	Director Vice President, Executive Corporate Officer Japan Business and Human Resources Development
Akihiro Okumura *	Director
Takayuki Katayama *	Director
Kanoko Oishi *	Director
Yoshihiro Noutsuka	Standing Corporate Auditor
Yutaka Mizuno**	Corporate Auditor
Koichi Matsuzawa **	Corporate Auditor
Seichiro Adachi **	Corporate Auditor

* The Outside Directors (indicated by an asterisk (*) next to their names) are Independent Officers (as set forth in Article 436-2, Paragraph 1 of the Securities Listing Regulations of the Tokyo Stock Exchange, Inc.; hereinafter, the same classification shall apply.)

The Outside Corporate Auditors (indicated by two asterisks ()) are Independent Officers.

Corporate Officers (excluding Corporate Officers who are also Members of the Board)

Masamichi Sato	Senior Corporate Officer Corporate Development Head of CSR and General Affairs Division
Takeshi Ito	Senior Corporate Officer Head of Japan Sales and Marketing, Prescription Pharmaceuticals
Naveed Shams	Senior Corporate Officer Chief Scientific Officer (CSO) Head of Global Research & Development President & CEO of Santen Inc.
Akihiro Tsujimura	Senior Corporate Officer Head of Asia Division
Atutoshi Ota	Senior Corporate Officer Head of Human Resources Development Division
Kazuo Koshiji	Senior Corporate Officer Chief Financial Officer (CFO) Head of Finance and Administration Division
Jyrki Liljeroos	Corporate Officer President of Santen Oy
Kenji Morishima	Corporate Officer Head of Global Pharmaceutical Technology Development
Akio Kimura	Corporate Officer Head of Global Quality Compliance
Noriaki Yamamoto	Corporate Officer Chief Information Officer (CIO) Head of Information Systems Division
Hiroyuki Yamazaki	Corporate Officer Head of Japan Prescription Pharmaceuticals Sales
Keizo Nakada	Corporate Officer Head of Global Product Supply
Shigeo Taniuchi	Corporate Officer Head of Santen Europe President of Santen Holdings EU B.V.

End.